{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T08:53:58Z","timestamp":1776329638400,"version":"3.50.1"},"reference-count":51,"publisher":"Baskent University","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Clin Transplant"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.6002\/ect.2021.0069","type":"journal-article","created":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T01:44:06Z","timestamp":1632275046000},"page":"549-557","source":"Crossref","is-referenced-by-count":4,"title":["De Novo and Recurrent Thrombotic Microangiopathy After Renal Transplantation: Current Concepts in Management"],"prefix":"10.6002","volume":"20","author":[{"given":"Fedaei","family":"Abbas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara Fedaei","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4021","reference":[{"key":"ref0","unstructured":"References"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"1. Shochet L, Kanellis J, Simpson I, Ta J, Mulley W. De novo thrombotic microangiopathy following simultaneous pancreas and kidney transplantation managed with eculizumab. Nephrology (Carlton). 2017;22 Suppl 1:23-27. doi:10.1111\/nep.12936","DOI":"10.1111\/nep.12936"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"2. Schwimmer J, Nadasdy TA, Spitalnik PF, Kaplan KL, Zand MS. De novo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy. Am J Kidney Dis. 2003;41(2):471-479. doi:10.1053\/ajkd.2003.50058","DOI":"10.1053\/ajkd.2003.50058"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"3. Radha S, Tameem A, Sridhar G, et al. Thrombotic microangiopathy in renal allografts. Indian J Nephrol. 2014;24(1):24-27. doi:10.4103\/0971-4065.125052","DOI":"10.4103\/0971-4065.125052"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"4. Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5(10):1844-1859. doi:10.2215\/CJN.02210310","DOI":"10.2215\/CJN.02210310"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"5. Noris M, Remuzzi G. Thrombotic microangiopathy after kidney transplantation. Am J Transplant. 2010;10(7):1517-1523. doi:10.1111\/j.1600-6143.2010.03156.x","DOI":"10.1111\/j.1600-6143.2010.03156.x"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"6. Cofiell R, Kukreja A, Bedard K, et al. Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Blood. 2015;125(21):3253-3262. doi:10.1182\/blood-2014-09-600411","DOI":"10.1182\/blood-2014-09-600411"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"7. Dedhia P, Govil A, Mogilishetty G, Alloway RR, Woodle ES, Abu Jawdeh BG. Eculizumab and belatacept for de novo atypical hemolytic uremic syndrome associated with CFHR3-CFHR1 deletion in a kidney transplant recipient: a case report. Transplant Proc. 2017;49(1):188-192. doi:10.1016\/j.transproceed.2016.11.008","DOI":"10.1016\/j.transproceed.2016.11.008"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"8. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361(17):1676-1687. doi:10.1056\/NEJMra0902814","DOI":"10.1056\/NEJMra0902814"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"9. Kwon O, Hong SM, Sutton TA, Temm CJ. Preservation of peritubular capillary endothelial integrity and increasing pericytes may be critical to recovery from postischemic acute kidney injury. Am J Physiol Renal Physiol. 2008;295(2):F351-359. doi:10.1152\/ajprenal.90276.2008","DOI":"10.1152\/ajprenal.90276.2008"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"10. Olie KH, Goodship TH, Verlaak R, et al. Posttransplantation cytomegalovirus-induced recurrence of atypical hemolytic uremic syndrome associated with a factor H mutation: successful treatment with intensive plasma exchanges and ganciclovir. Am J Kidney Dis. 2005;45(1):e12-15. doi:10.1053\/j.ajkd.2004.09.012","DOI":"10.1053\/j.ajkd.2004.09.012"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"11. Ardalan MR, Shoja MM, Tubbs RS, Esmaili H, Keyvani H. Postrenal transplant hemophagocytic lymphohistiocytosis and thrombotic microangiopathy associated with parvovirus b19 infection. Am J Transplant. 2008;8(6):1340-1344. doi:10.1111\/j.1600-6143.2008.02244.x","DOI":"10.1111\/j.1600-6143.2008.02244.x"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"12. Le Quintrec M, Lionet A, Kamar N, et al. Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation. Am J Transplant. 2008;8(8):1694-1701. doi:10.1111\/j.1600-6143.2008.02297.x","DOI":"10.1111\/j.1600-6143.2008.02297.x"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"13. Karthikeyan V, Parasuraman R, Shah V, Vera E, Venkat KK. Outcome of plasma exchange therapy in thrombotic microangiopathy after renal transplantation. Am J Transplant. 2003;3(10):1289-1294. doi:10.1046\/j.1600-6143.2003.00222.x","DOI":"10.1046\/j.1600-6143.2003.00222.x"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"14. Zuber J, Le Quintrec M, Sberro-Soussan R, Loirat C, Fremeaux-Bacchi V, Legendre C. New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol. 2011;7(1):23-35. doi:10.1038\/nrneph.2010.155","DOI":"10.1038\/nrneph.2010.155"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"15. Artz MA, Steenbergen EJ, Hoitsma AJ, Monnens LA, Wetzels JF. Renal transplantation in patients with hemolytic uremic syndrome: high rate of recurrence and increased incidence of acute rejections. Transplantation. 2003;76(5):821-826. doi:10.1097\/01.TP.0000085083.74065.1B","DOI":"10.1097\/01.TP.0000085083.74065.1B"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"16. Oyen O, Strom EH, Midtvedt K, et al. Calcineurin inhibitor-free immunosuppression in renal allograft recipients with thrombotic microangiopathy\/hemolytic uremic syndrome. Am J Transplant. 2006;6(2):412-418. doi:10.1111\/j.1600-6143.2005.01184.x","DOI":"10.1111\/j.1600-6143.2005.01184.x"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"17. Bresin E, Daina E, Noris M, et al. Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. Clin J Am Soc Nephrol. 2006;1(1):88-99. doi:10.2215\/CJN.00050505","DOI":"10.2215\/CJN.00050505"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"18. Karpman D, Sartz L, Johnson S. Pathophysiology of typical hemolytic uremic syndrome. Semin Thromb Hemost. 2010;36(6):575-585. doi:10.1055\/s-0030-1262879","DOI":"10.1055\/s-0030-1262879"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"19. Satoskar AA, Pelletier R, Adams P, et al. De novo thrombotic microangiopathy in renal allograft biopsies-role of antibody-mediated rejection. Am J Transplant. 2010;10(8):1804-1811. doi:10.1111\/j.1600-6143.2010.03178.x","DOI":"10.1111\/j.1600-6143.2010.03178.x"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"20. Chua JS, Baelde HJ, Zandbergen M, et al. Complement factor C4d is a common denominator in thrombotic microangiopathy. J Am Soc Nephrol. 2015;26(9):2239-2247. doi:10.1681\/ASN.2014050429","DOI":"10.1681\/ASN.2014050429"},{"key":"ref21","unstructured":"21. Wrenn SM, Gibson PC, Hain DS, et al. Development of de novo hemolytic uremic syndrome post-transplant and the role of donor specific antibodies: a case report and review of literature. J immuno Biol. 2015;1(1):1-6. doi:10.4172\/ jib.1000101"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"22. Broeders EN, Stordeur P, Rorive S, Dahan K. A 'silent', new polymorphism of factor H and apparent de novo atypical haemolytic uraemic syndrome after kidney transplantation. BMJ Case Rep. 2014;2014. doi:10.1136\/bcr-2014-207630","DOI":"10.1136\/bcr-2014-207630"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"23. Kaplan BS, Ruebner RL, Spinale JM, Copelovitch L. Current treatment of atypical hemolytic uremic syndrome. Intractable Rare Dis Res. 2014;3(2):34-45. doi:10.5582\/irdr.2014.01001","DOI":"10.5582\/irdr.2014.01001"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"24. Delvaeye M, Noris M, De Vriese A, et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361(4):345-357. doi:10.1056\/NEJMoa0810739","DOI":"10.1056\/NEJMoa0810739"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"25. Reynolds JC, Agodoa LY, Yuan CM, Abbott KC. Thrombotic microangiopathy after renal transplantation in the United States. Am J Kidney Dis. 2003;42(5):1058-1068. doi:10.1016\/j.ajkd.2003.07.008","DOI":"10.1016\/j.ajkd.2003.07.008"},{"key":"ref26","unstructured":"26. Rolla D, Fontana I, Ravetti JL, et al. De novo post-transplant thrombotic microangiopathy localized only to the graft in autosomal dominant polycystic kidney disease with thrombophilia. J Renal Inj Prev. 2015;4(4):135-138. doi:10.12861\/jrip.2015.28"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"27. Loirat C, Fremeaux-Bacchi V. Hemolytic uremic syndrome recurrence after renal transplantation. Pediatr Transplant. 2008;12(6):619-629. doi:10.1111\/j.1399-3046.2008.00910.x","DOI":"10.1111\/j.1399-3046.2008.00910.x"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"28. Caprioli J, Noris M, Brioschi S, et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006;108(4):1267-1279. doi:10.1182\/blood-2005-10-007252","DOI":"10.1182\/blood-2005-10-007252"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"29. Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA, et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2007;18(8):2392-2400. doi:10.1681\/ASN.2006080811","DOI":"10.1681\/ASN.2006080811"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"30. Seitz B, Albano L, Vocila F, et al. Recurrence of hemolytic uremic syndrome after renal transplantation. Transplant Proc. 2007;39(8):2583-2585. doi:10.1016\/j.transproceed.2007.08.021","DOI":"10.1016\/j.transproceed.2007.08.021"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"31. Bren A, Pajek J, Grego K, et al. Follow-up of kidney graft recipients with cyclosporine-associated hemolytic-uremic syndrome and thrombotic microangiopathy. Transplant Proc. 2005;37(4):1889-1891. doi:10.1016\/j.transproceed.2005.02.112","DOI":"10.1016\/j.transproceed.2005.02.112"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"32. Donne RL, Abbs I, Barany P, et al. Recurrence of hemolytic uremic syndrome after live related renal transplantation associated with subsequent de novo disease in the donor. Am J Kidney Dis. 2002;40:E22. doi:10.1053\/ajkd.2002.36938","DOI":"10.1053\/ajkd.2002.36938"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"33. Kwon T, Dragon-Durey MA, Macher MA, et al. Successful pre-transplant management of a patient with anti-factor H autoantibodies-associated haemolytic uraemic syndrome. Nephrol Dial Transplant. 2008;23(6):2088-2090. doi:10.1093\/ndt\/gfn063","DOI":"10.1093\/ndt\/gfn063"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"34. Le Quintrec M, Zuber J, Noel LH, et al. Anti-Factor H autoantibodies in a fifth renal transplant recipient with atypical hemolytic and uremic syndrome. Am J Transplant. 2009;9(5):1223-1229. doi:10.1111\/j.1600-6143.2009.02586.x","DOI":"10.1111\/j.1600-6143.2009.02586.x"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"35. Le Quintrec M, Zuber J, Moulin B, et al. Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant. 2013;13(3):663-675. doi:10.1111\/ajt.12077","DOI":"10.1111\/ajt.12077"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"36. Fremeaux-Bacchi V, Fakhouri F, Garnier A, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013;8(4):554-562. doi:10.2215\/CJN.04760512","DOI":"10.2215\/CJN.04760512"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"37. Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368(23):2169-2181. doi:10.1056\/NEJMoa1208981","DOI":"10.1056\/NEJMoa1208981"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"38. Zuber J, Le Quintrec M, Krid S, et al. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant. 2012;12(12):3337-3354. doi:10.1111\/j.1600-6143.2012.04252.x","DOI":"10.1111\/j.1600-6143.2012.04252.x"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"39. Ardissino G, Possenti I, Tel F, Testa S, Salardi S, Ladisa V. Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: an update. Am J Kidney Dis. 2015;66(1):172-173. doi:10.1053\/j.ajkd.2015.04.010","DOI":"10.1053\/j.ajkd.2015.04.010"},{"key":"ref40","unstructured":"40. National Institute for Health and Care Excellence. Eculizumab for treating atypical haemolytic uraemic syndrome; 2015. https:\/\/www.nice.org.uk\/guidance\/hst1\/documents\/atypical-haemolytic-uraemic-syndrome"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"41. Ashman N, Chapagain A, Dobbie H, Raftery MJ, Sheaff MT, Yaqoob MM. Belatacept as maintenance immunosuppression for postrenal transplant de novo drug-induced thrombotic microangiopathy. Am J Transplant. 2009;9(2):424-427. doi:10.1111\/j.1600-6143.2008.02482.x","DOI":"10.1111\/j.1600-6143.2008.02482.x"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"42. Midtvedt K, Bitter J, Dorje C, Bjorneklett R, Holdaas H. Belatacept as immunosuppression in patient with recurrence of hemolytic uremic syndrome after renal transplantation. Transplantation. 2009;87(12):1901-1903. doi:10.1097\/TP.0b013e3181a991ca","DOI":"10.1097\/TP.0b013e3181a991ca"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"43. Watt T, Warshaw B, Katzenstein HM. Atypical hemolytic uremic syndrome responsive to steroids and intravenous immune globulin. Pediatr Blood Cancer. 2009;53(1):90-91. doi:10.1002\/pbc.21951","DOI":"10.1002\/pbc.21951"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"44. Lionet A, Provot F, Glowacki F, Fremeaux-Bacchi V, Hazzan M. A case of adult atypical haemolytic uraemic syndrome related to anti-factor H autoantibodies successfully treated by plasma exchange, corticosteroids and rituximab. NDT Plus. 2009;2(6):458-460. doi:10.1093\/ndtplus\/sfp109","DOI":"10.1093\/ndtplus\/sfp109"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"45. Larrea CF, Cofan F, Oppenheimer F, Campistol JM, Escolar G, Lozano M. Efficacy of eculizumab in the treatment of recurrent atypical hemolytic-uremic syndrome after renal transplantation. Transplantation. 2010;89(7):903-904. doi:10.1097\/TP.0b013e3181ccd80d","DOI":"10.1097\/TP.0b013e3181ccd80d"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"46. Nurnberger J, Philipp T, Witzke O, et al. Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med. 2009;360(5):542-544. doi:10.1056\/NEJMc0808527","DOI":"10.1056\/NEJMc0808527"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"47. Chatelet V, Lobbedez T, Fremeaux-Bacchi V, Ficheux M, Ryckelynck JP, Hurault de Ligny B. Eculizumab: safety and efficacy after 17 months of treatment in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome: case report. Transplant Proc. 2010;42(10):4353-4355. doi:10.1016\/j.transproceed.2010.09.125","DOI":"10.1016\/j.transproceed.2010.09.125"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"48. Davin JC, Gracchi V, Bouts A, Groothoff J, Strain L, Goodship T. Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation. Am J Kidney Dis. 2010;55(4):708-711. doi:10.1053\/j.ajkd.2009.08.011","DOI":"10.1053\/j.ajkd.2009.08.011"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"49. Wong E, Challis R, Sheerin N, Johnson S, Kavanagh D, Goodship TH. Patient stratification and therapy in atypical haemolytic uraemic syndrome (aHUS). Immunobiology. 2016;221(6):715-718. doi:10.1016\/j.imbio.2015.05.002","DOI":"10.1016\/j.imbio.2015.05.002"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"50. van den Brand JA, Verhave JC, Adang EM, Wetzels JF. Cost-effectiveness of eculizumab treatment after kidney transplantation in patients with atypical haemolytic uraemic syndrome. Nephrol Dial Transplant. 2017;32(suppl_1):i115-i122. doi:10.1093\/ndt\/gfw353","DOI":"10.1093\/ndt\/gfw353"}],"container-title":["Experimental and Clinical Transplantation"],"original-title":[],"deposited":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T07:27:02Z","timestamp":1657092422000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.ectrx.org\/detail\/archive\/2022\/20\/6\/0\/549\/0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"URL":"https:\/\/doi.org\/10.6002\/ect.2021.0069","relation":{},"ISSN":["1304-0855","2146-8427"],"issn-type":[{"value":"1304-0855","type":"print"},{"value":"2146-8427","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6]]}}}